Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy in Contemporary Clinical Practice

This symposium will provide heart failure specialists and care providers insights into the recent guidelines for the management of obstructive hypertrophic cardiomyopathy (HCM) from the AHA/ACC and the European Society of Cardiology.  Specifically, the appropriate and practical use of cardiac myosin inhibitors in clinical practice will be highlighted by a diverse group of HCM specialists.

• • Introduction
  • Guideline update on the treatment of obstructive HCM
  • Major findings from randomized trials of cardiac myosin inhibitors (CMIs)
  • Real world use of CMI in clinical practice:  What I’ve learned
  • Key role of cardiac imaging in treatment selection
  • Q&A